In the BioHarmony Drug Report Database
Macimorelin
Macrilen, Macimorelin Aeterna Zentaris (macimorelin) is a small molecule pharmaceutical. Macimorelin was first approved as Macrilen on 2017-12-20. It has been approved in Europe to treat endocrine diagnostic techniques. The pharmaceutical is active against growth hormone secretagogue receptor type 1. Macrilen’s patent is valid until 2027-10-12 (FDA).
Trade Name
|
Macimorelin Aeterna Zentaris |
|---|---|
Common Name
|
macimorelin |
ChEMBL ID
|
CHEMBL278623 |
Indication
|
endocrine diagnostic techniques |
Drug Class
|
Prehormones or hormone-release stimulating peptides: growth hormone-release stimulating peptides |
Image (chem structure or protein)